Return to content in this issue
Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2: a case description
Pecori D1, Della Siega P1, Sozio E2, Barbano E3, Mazzoran L3, Zanichelli A4, Sbrana F5, Federico I3, Bassi F6, Fabris M7, Vendramin I8, Sbrojavacca R1, Tascini C1
1SOC Malattie Infettive, Azienda Sanitaria Universitaria Integrata di Udine, Udine. Italy.
2North-West District, Tuscany Health Care, Spedali Riuniti Livorno, Emergency Department, Livorno. Italy.
3Medicina D'Urgenza e Pronto Soccorso, Azienda Sanitaria Universitaria Integrata di Udine, Udine. Italy.
4U.O. Medicina Generale, ASST Fatebenefratelli Sacco, Ospedale “Luigi Sacco”, Milano. Italy.
5U.O. Lipoapheresis and Center for Inherited Dyslipidemias - Fondazione Toscana Gabriele Monasterio, Pisa. Italy.
6SOC Anestesia e Rianimazione 2, Azienda Sanitaria Universitaria Integrata di Udine, Udine. Italy.
7Institute of Clinical Pathology, Azienda Sanitaria Universitaria Friuli Centrale, Udine. Italy.
8Cardiothoracic Department; Division of Cardiac Surgery, Azienda Sanitaria Universitaria Friuli Centrale, Udine. Italy.
J Investig Allergol Clin Immunol 2021; Vol. 31(5)
doi: 10.18176/jiaci.0659
Key words: COVID-19, Icatibant, Severe Acute Respiratory Syndrome, SARS-CoV-2, Contact system
| Title | Type | Size | |
|---|---|---|---|
 |
doi10.18176_jiaci.0659_material-suppl.pdf | 422.76 Kb |
